Video: Eyeing phase II clinical trial in HCC patients with milciclib

Dr. Kunwar Shailubhai talks to Tip TV about Tiziana receiving approval to start Phase IIa trials to test its leading compound milciclib, a CDK inhibitor as a treatment for hepatocellular carcinoma (HCC).

The release as fetched from its publisher. tizianalifesciences.com ↗